Milestone Pharmaceuticals Inc. Common Shares - MIST STOCK NEWS

Milestone Pharmaceuticals (Nasdaq: MIST) announced successful results from the Phase 3 RAPID trial of etripamil, a nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). The trial achieved its primary endpoint, with 64.3% of patients converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001). Safety data indicated tolerability, with no serious adverse events reported. Milestone plans to file a New Drug Application (NDA) with the U.S. FDA in mid-2023, further supporting the potential for etripamil as a self-administered treatment.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 12:00 p.m. ET in New York, NY. The presentation will be accessible via live webcast on Milestone's website, with an archived replay available for 90 days. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate etripamil in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation. For more details, visit www.milestonepharma.com.

Milestone Pharmaceuticals Inc. (MIST) reported substantial progress in its Phase 3 PSVT clinical program, achieving the required 180 confirmed events for the RAPID study. The topline data readout is expected in mid-second half of 2022. Financially, the company had $86.2 million in cash as of June 30, 2022, but incurred operating losses of $16.8 million for Q2, marking a significant decline from a prior year income of $0.7 million. Research and development expenses rose to $10.7 million due to advancing clinical trials, while general and administrative costs increased to $3.9 million.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 PM ET in New York, NY. Joseph Oliveto, the President and CEO, will lead the discussion. A live webcast will be accessible in the News & Events section of Milestone's website, with an archived replay available for 90 days post-event. Milestone focuses on innovative cardiovascular medicines, with its lead candidate etripamil in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced the granting of incentive stock options for 92,000 common shares to three new employees, exercisable at $5.48 per share, the closing price on May 16, 2022. This move, compliant with NASDAQ's inducement grant exception, aims to attract talent as part of their employment compensation. The options have a 10-year term and will vest over four years, starting with 25% vesting after the first year. Milestone is advancing its lead candidate, etripamil, through clinical trials targeting cardiovascular conditions.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded chat will be accessible starting May 24, 2022, at 7:00 am ET via their website. Milestone is focused on innovative cardiovascular medicines, with their lead product candidate, etripamil, in a Phase 3 clinical program for treating paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals (Nasdaq: MIST) reported first-quarter financial results for 2022, showcasing a cash position of $100.2 million. The company continues to advance its Phase 3 program for etripamil, targeting patients with PSVT, with key topline data readout expected in mid-second half 2022. Recent data from the NODE-302 study indicates a 60.2% conversion rate for PSVT episodes with low ED intervention needs. The operating loss for Q1 2022 was $14 million, an increase from the prior year's $12.5 million.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) presented data from the NODE-302 Phase 3 study of etripamil nasal spray, showcasing its effectiveness in treating paroxysmal supraventricular tachycardia (PSVT). The study indicated that 85% of participants from the previous NODE-301 chose to continue, with a conversion rate of 60.2% at 30 minutes post-administration. The treatment was well-tolerated and significantly reduced emergency department visits. Results are being shared at the Heart Rhythm 2022 conference, indicating promising advancements in self-managed PSVT care.

Milestone Pharmaceuticals (Nasdaq: MIST) announced on April 15, 2022, the grant of stock options to new employees as part of their compensation. One employee received 65,000 options with an exercise price of $6.85, and another received 36,000 options at $6.93. These grants, approved under NASDAQ's inducement grant exception, vest over four years. Milestone is developing innovative cardiovascular medicines, with its lead candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation.